newsfilter
← Latest News
Business Wire·

AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million

All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a